Bayer, Merck KGaA spend big bucks for market share in China

Carly Helfand Multinational pharma companies have been targeting China for years with an eye on its aging population, expanding middle class and growing incidence of chronic maladies ...

Daiichi Sankyo’s new a-fib drug heads toward FDA approval and a crowded market

Damian Garde A panel of FDA advisers voted in favor of approving Daiichi Sankyo's irregular heartbeat treatment edoxaban, heralding its ability to break up blood clots and improving ...

New wave of HER2 meds to fuel huge leap in breast cancer market

Carly Helfand HER2-positive breast cancer treatments already do pretty well for themselves, with Roche's Herceptin taking the No. 8 spot last year on the world's list of best-selling ...

It’s megablockbuster halfsies for Sanofi, Amgen in next new cholesterol market

Tracy Staton When is cholesterol fighting a game of six of one, half dozen of the other? Could be when the contest is between Amgen and its PCSK9 inhibitor evolocumab, and Sanofi and ...

Can Boehringer carve out space in a crowded COPD market with new approval?

Carly Helfand The COPD market has its fair share of contenders, but that's not stopping Boehringer Ingelheim from joining the party. The German drugmaker has nabbed FDA approval ...

Novartis’ Enbrel beater nears a soon-to-crowd psoriasis market

Damian Garde Novartis' in-development drug secukinumab beat out the blockbuster Enbrel in improving symptoms of psoriasis in Phase III, improving the company's odds of success ...

Cancer-drug market zooms toward $100B, thanks to costly targeted therapies

Tracy Staton What's a blockbuster market worth? In the case of cancer treatments, the answer will soon be $ 100 billion. According to a new study by the IMS Institute for Healthcare ...

Radius dials up a $92M IPO pitch despite tepid market for biotechs

Damian Garde Radius Health is betting the promise of its bone-boosting drug will sway investors to buy into its planned $ 92 million IPO, forging ahead in what has become a shaky market ...

FDA rejects Durect’s pitch to market post-operative pain therapy

John Carroll FierceBiotech News

New data positions Astellas prostate cancer med Xtandi to grab market share from J&J’s Zytiga

Tracy Staton Some new data on the prostate cancer drug Xtandi promises to heat up competition with Johnson & Johnson's Zytiga. Medivation and its partner Astellas Pharma unveiled ...

Indian drugmakers grab big share of U.K. pharma market

Tracy Staton In the U.K., drugs produced in India are almost as common as those made in Britain, a new report from the Medicines and Healthcare Products Regulatory Agency says. FiercePharma ...

Ariad returns Iclusig to market but with more restrictions and smaller patient pool

Eric Palmer Ariad Pharmaceuticals is back in the market with Iclusig. The FDA is allowing the Cambridge, MA-based company to again sell the leukemia drug, but with tighter restrictions ...
Page 2 of 812345...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS